{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.94","upperLimit":"0.98","value":"0.96"},{"groupId":"OG001","lowerLimit":"0.97","upperLimit":"1.00","value":"1.00"}]}],"title":"2 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.91","upperLimit":"0.95","value":"0.93"},{"groupId":"OG001","lowerLimit":"0.97","upperLimit":"1.00","value":"1.00"}]}],"title":"4 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"0.94","value":"0.92"},{"groupId":"OG001","lowerLimit":"0.97","upperLimit":"1.00","value":"1.00"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.88","upperLimit":"0.93","value":"0.90"},{"groupId":"OG001","lowerLimit":"0.97","upperLimit":"1.00","value":"1.00"}]}],"title":"9 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"overall response = complete response (CR) + partial response (PR) per RECIST 1.0 Time to overall response (CR or PR) based on investigator is the time between date of randomization/start of treatment until first documented response (CR or PR). This analysis included all patients/responders. Patients who did not achieve a confirmed PR or CR were censored at last adequate tumor assessment date when they did not progress. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"NUMBER","populationDescription":"All randomized patients were included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"2, 4, 6, 9 months","title":"Proportion of Patients With Having no Overall Response Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Proportion of patients"}